Cooper Companies COO · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
63.93
+2.52%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cooper Companies
From its filings with the US Securities and Exchange Commission
Cooper Companies is based in San Ramon, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker COO. It is a member of the S&P 500. The SEC classifies its business as ophthalmic goods. In the fiscal year to 31 October 2025, it reported revenue of $4.09bn and net income of $374.9m. At that date it held total assets of $12.39bn and shareholders' equity of $8.24bn. By region, United States accounted for 50.2%, followed by Europe at 30.6% and Rest of World at 19.2%.
The Cooper Companies, Inc. (Cooper, we or the Company), is a leading global medical device company focused on helping people experience life's beautiful moments. Headquartered in San Ramon, California, Cooper sells products in over 130 countries and positively impacts over fifty million lives each year.
CooperVision is a global manufacturer providing products for contact lens wearers. CooperVision develops, manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. CooperVision designs its products to address vision challenges such as astigmatism, presbyopia and myopia with a broad collection of spherical, toric and multifocal contact lenses. CooperVision offers contact lenses in materials like silicone hydrogel Aquaform technology. CooperVision also manufactures and markets myopia management products, including the internally developed MiSight 1 day lens, as well as other specialty eyecare products such as orthokeratology (ortho-k) and scleral lenses. In November 2019, the MiSight 1 day contact lens became the first and only product approved by the United States Food and Drug Administration (FDA) for slowing the progression of myopia in children aged 8-12 at the initiation of treatment. CooperVision received approval for use of the MiSight 1 day lens in China from Chinese National Medical Products Administration (NMPA) in August 2021 and in Japan from the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2025.
Quoted from its 10-K, filed 5 Dec 2025. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 6 Dec 1983
- Employees
- 15,000
- Website
- coopercos.com ↗
- Head office
- 6101 BOLLINGER CANYON ROAD, SAN RAMON, CA, 94583
- Incorporated in
- DE
- Classification
- Ophthalmic Goods
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Robert WeissIndependent Chairman of the Board, since 1989$472,025
- Mr. Albert WhitePresident, Chief Executive Officer, Director, since 2006$15.4m
- Mr. Brian AndrewsChief Financial Officer, Executive Vice President, Treasurer$3.7m
- Ms. Holly SheffieldPresident - CooperSurgical, Inc$3.4m
- Mr. Gerard WarnerPresident, CooperVision, Inc$3.1m
- Mr. Daniel McbrideChief Operating Officer, Executive Vice President$4.8m
- Mr. Agostino RicupatiSenior Vice President - Finance and Tax, Chief Accounting Officer$1.8m
- Mr. Nicholas KhadderVice President, General Counsel, Corporate Secretary
- Ms. Barbara CarboneIndependent Director
- Ms. Colleen JayIndependent Director$340,032
- Mr. Lawrence KurziusIndependent Director$405,911
- Ms. Cynthia LuccheseIndependent Director$320,032
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 63
- Environment
- 55
- Social
- 65
- Governance
- 69
- Direct emissions (scope 1)
- 58,155 t
- Energy emissions (scope 2)
- 30,032 t
- Women in the workforce
- 49%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CooperVision manufactures contact lenses in five global facilities including the United Kingdom and Puerto Rico.
- The company employs 12000 full-time staff across its two main business units CooperVision and CooperSurgical.
- CooperVision serves three primary regions Americas, Europe Middle East and Africa, and Asia Pacific effectively.
Weaknesses
- The business description lists 15000 employees but the text states the firm employs 12000 full-time employees.
- CooperSurgical focuses on women's health and fertility diagnostics without mentioning broader medical device diversification.
- The company operates through only two business units CooperVision and CooperSurgical limiting operational breadth.
Opportunities
- CooperVision develops multifocal and toric lens products which address specific vision correction market needs.
- CooperSurgical advances family health through a portfolio of products focusing on fertility and diagnostics.
- CooperVision offers single-use and monthly contact lenses catering to diverse consumer preferences in vision care.
Threats
- CooperVision products are manufactured in multiple countries including Hungary and Costa Rica facing supply chain risks.
- The company relies on CooperVision for soft contact lenses which may face market saturation pressures.
- CooperSurgical's focus on women's health limits its exposure to other high-growth medical device segments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.